| Year |
Citation |
Score |
| 2020 |
Turner JG, Cui Y, Bauer AA, Dawson JL, Gomez JA, Kim J, Cubitt CL, Nishihori T, Dalton WS, Sullivan DM. Melphalan and exportin 1 inhibitors exert synergistic anti-tumor effects in preclinical models of human multiple myeloma. Cancer Research. PMID 33023948 DOI: 10.1158/0008-5472.CAN-19-0677 |
0.361 |
|
| 2019 |
Sweet K, Komrokji RS, Padron E, Cubitt CL, Turner JG, Zhou J, List AF, Sallman DA, Dawson JL, Sullivan DM, Chavez J, Shah BD, Lancet JE. Phase I clinical trial of selinexor in combination with daunorubicin and cytarabine in previously untreated poor-risk acute myeloid leukemia. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31636097 DOI: 10.1158/1078-0432.Ccr-19-2169 |
0.348 |
|
| 2019 |
Turner JG, Dawson J, Bauer A, Gomez J, Baloglu E, Landesman Y, Sullivan DM. Abstract 285: Ixazomib combined with the nuclear export inhibitors selinexor or eltanexor for the treatment of multiple myeloma Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-285 |
0.332 |
|
| 2017 |
Turner JG. Abstract 4049: The synergistic effect of melphalan and XPO1 inhibition in preclinical models of multiple myeloma Cancer Research. 77: 4049-4049. DOI: 10.1158/1538-7445.Am2017-4049 |
0.489 |
|
| 2016 |
Turner JG, Kashyap T, Dawson JL, Gomez J, Bauer AA, Grant S, Dai Y, Shain KH, Meads M, Landesman Y, Sullivan DM. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma. Oncotarget. PMID 27806331 DOI: 10.18632/Oncotarget.12969 |
0.481 |
|
| 2016 |
Turner JG, Dawson JL, Grant S, Shain KH, Dalton WS, Dai Y, Meads M, Baz R, Kauffman M, Shacham S, Sullivan DM. Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors. Journal of Hematology & Oncology. 9: 73. PMID 27557643 DOI: 10.1186/S13045-016-0304-Z |
0.387 |
|
| 2016 |
Baz RC, Shain KH, Alsina M, Brayer J, Rashal T, Cooksey JL, Turner JG, Dawson J, Sullivan D. Phase I trial of the combination of selinexor (SEL), liposomal doxorubicin (DOX) and dexamethasone (Dex) for relapsed and refractory multiple myeloma (RRMM). Journal of Clinical Oncology. 34: 8013-8013. DOI: 10.1200/Jco.2016.34.15_Suppl.8013 |
0.324 |
|
| 2016 |
Cui Y, Turner JG, Dawson JL, Gomez JA, Shain KH, Meads MB, Baloglu E, Dalton WS, Nishihori T, Sullivan DM. The Synergistic Effect of Melphalan and XPO1 Inhibition in Pre-Clinical Models of Multiple Myeloma Blood. 128: 5662-5662. DOI: 10.1182/Blood.V128.22.5662.5662 |
0.492 |
|
| 2016 |
Cornell RF, Rossi AC, Baz R, Hofmeister CC, Shustik C, Richter JR, Chen C, Vogl DT, Shacham S, Baloglu E, Senapedis W, Ellis J, Friedlander S, Choe-Juliak C, Cubitt CL, ... Turner JG, et al. A Phase 1/2 Study of the Second Generation Selective Inhibitor of Nuclear Export (SINE) Compound, KPT-8602, in Patients with Relapsed Refractory Multiple Myeloma Blood. 128: 4509-4509. DOI: 10.1182/Blood.V128.22.4509.4509 |
0.328 |
|
| 2016 |
Turner JG, Kashyap T, Dawson JL, Gomez JA, Bauer A, Grant S, Dai Y, Shain KH, Meads MB, Landesman Y, Sullivan DM. Combination Therapy with Bortezomib or Carfilzomib and Selinexor Induces Nuclear Localization of Ikbα and Overcomes Acquired Proteasome Inhibitor Resistance in Human Multiple Myeloma Blood. 128: 3299-3299. DOI: 10.1182/Blood.V128.22.3299.3299 |
0.499 |
|
| 2016 |
Zhou L, Chen S, Zhang Y, Kmieciak M, Leng Y, Li L, Lin H, Turner J, Sullivan D, Dai Y, Grant S. Abstract 3020: Targeting both canonical and non-canonical NF-kB pathways by the IAP antagonist birinapant potentiates bortezomib anti-myeloma activity Cancer Research. 76: 3020-3020. DOI: 10.1158/1538-7445.Am2016-3020 |
0.473 |
|
| 2016 |
Turner JG, Dawson JL, Sullivan DM. Abstract 289: Melphalan and XPO1 inhibition are synergistic in pre-clinical models of multiple myeloma Cancer Research. 76: 289-289. DOI: 10.1158/1538-7445.Am2016-289 |
0.487 |
|
| 2015 |
Sullivan DM, Kashyap T, Dawson JL, Landesman Y, Grant S, Shain KH, Dai Y, Kauffman M, Shacham S, Turner JG. Combination Therapy of Selinexor with Bortezomib or Carfilzomib Overcomes Drug Resistance to Proteasome Inhibitors (PI) in Human Multiple Myeloma Blood. 126: 3048-3048. DOI: 10.1182/Blood.V126.23.3048.3048 |
0.489 |
|
| 2015 |
Turner JG, Dawson JL, Cubitt CL, Baluglo E, Grant S, Dai Y, Shain KH, Dalton WS, Shacham S, Senapedis W, Sullivan DM. Next Generation XPO1 Inhibitor KPT-8602 for the Treatment of Drug-Resistant Multiple Myeloma Blood. 126: 1818-1818. DOI: 10.1182/Blood.V126.23.1818.1818 |
0.491 |
|
| 2015 |
Turner JG, Dawson JL, Cubitt C, Nishihori T, Anasetti C, Alsina M, Baz RC, Kauffman M, Shacham S, Dalton WS, Sullivan DM. Abstract 4434: Selinexor and melphalan combination therapy for the treatment of multiple myeloma Cancer Research. 75: 4434-4434. DOI: 10.1158/1538-7445.Am2015-4434 |
0.487 |
|
| 2014 |
Turner JG, Dawson J, Cubitt CL, Baz R, Sullivan DM. Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents. Seminars in Cancer Biology. 27: 62-73. PMID 24631834 DOI: 10.1016/J.Semcancer.2014.03.001 |
0.444 |
|
| 2014 |
Turner JG, Dawson JL, Grant S, Shain KH, Dai Y, Cubitt C, Baz R, Nishihori T, Kauffman M, Shacham S, Sullivan DM. Melphalan and XPO1 Inhibitor Combination Therapy for the Treatment of Multiple Myeloma Blood. 124: 2084-2084. DOI: 10.1182/Blood.V124.21.2084.2084 |
0.492 |
|
| 2014 |
Turner JG, Shain KH, Dai Y, Dawson JL, Cubitt CL, Shacham S, Kauffman M, Grant S, Sullivan DM. Abstract 1772: Overcoming drug-resistance in multiple myeloma by CRM1 inhibitor combination therapy Cancer Research. 74: 1772-1772. DOI: 10.1158/1538-7445.Am2014-1772 |
0.481 |
|
| 2013 |
Turner JG, Dawson J, Emmons MF, Cubitt CL, Kauffman M, Shacham S, Hazlehurst LA, Sullivan DM. CRM1 Inhibition Sensitizes Drug Resistant Human Myeloma Cells to Topoisomerase II and Proteasome Inhibitors both In Vitro and Ex Vivo. Journal of Cancer. 4: 614-25. PMID 24155773 DOI: 10.7150/Jca.7080 |
0.495 |
|
| 2013 |
Veerapathran A, Pidala J, Beato F, Betts B, Kim J, Turner JG, Hellerstein MK, Yu XZ, Janssen W, Anasetti C. Human regulatory T cells against minor histocompatibility antigens: ex vivo expansion for prevention of graft-versus-host disease. Blood. 122: 2251-61. PMID 23908471 DOI: 10.1182/Blood-2013-03-492397 |
0.301 |
|
| 2013 |
Turner JG, Rowe TC, Ostrov D, Dawson JL, Pernazza D, Lawrence NJ, Sullivan DM. Targeting The Nuclear Export Signal In Multiple Myeloma Blood. 122: 1925-1925. DOI: 10.1182/Blood.V122.21.1925.1925 |
0.426 |
|
| 2013 |
Turner JG, Dawson JL, Cubitt CL, Kauffman M, Shacham S, Sullivan DM. Abstract 2066: Combination therapy of human multiple myeloma using proteosome and CRM1 inhibitors. Cancer Research. 73: 2066-2066. DOI: 10.1158/1538-7445.Am2013-2066 |
0.491 |
|
| 2012 |
Turner JG, Dawson J, Sullivan DM. Nuclear export of proteins and drug resistance in cancer. Biochemical Pharmacology. 83: 1021-32. PMID 22209898 DOI: 10.1016/J.Bcp.2011.12.016 |
0.4 |
|
| 2012 |
Turner JG, Dawson JL, Sullivan DM. Casein Kinase II Modulates Topoisomerase II Alpha Nuclear Export and Drug Sensitivity in Multiple Myeloma Blood. 120: 4032-4032. DOI: 10.1182/Blood.V120.21.4032.4032 |
0.432 |
|
| 2012 |
Turner JG, Dawson JL, Sullivan DM. Abstract 1771: KOS-2464, a novel CRM1 inhibitor and a potential drug for multiple myeloma and leukemia Cancer Research. 72: 1771-1771. DOI: 10.1158/1538-7445.Am2012-1771 |
0.506 |
|
| 2011 |
Turner JG, Dawson JL, Shachem S, Kaufman M, Sullivan DM. Abstract B176: Novel inhibitors of nuclear export as a treatment for multiple myeloma. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-B176 |
0.492 |
|
| 2010 |
Shacham S, Turner JG, Nir R, Draetta G, Sandanayaka V, Shechter S, Kauffman M, Sullivan D. Preclinical Development of Small-Molecule CRM1 Inhibitors as Novel Therapy for the Treatment of Myeloma and Other Hematological Malignancies Blood. 116: 3012-3012. DOI: 10.1182/Blood.V116.21.3012.3012 |
0.498 |
|
| 2010 |
Turner JG, Dawson JL, Ciaravino EJ, Koomen JM, Sullivan DM. Abstract 725: Protein kinase-CK2 inhibition as a potential treatment for multiple myeloma Cancer Research. 70: 725-725. DOI: 10.1158/1538-7445.Am10-725 |
0.441 |
|
| 2009 |
Turner JG, Marchion DC, Dawson JL, Emmons MF, Hazlehurst LA, Washausen P, Sullivan DM. Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition. Cancer Research. 69: 6899-905. PMID 19690141 DOI: 10.1158/0008-5472.Can-09-0484 |
0.452 |
|
| 2009 |
Marchion DC, Bicaku E, Turner JG, Schmitt ML, Morelli DR, Munster PN. HDAC2 regulates chromatin plasticity and enhances DNA vulnerability. Molecular Cancer Therapeutics. 8: 794-801. PMID 19372552 DOI: 10.1158/1535-7163.Mct-08-0985 |
0.352 |
|
| 2009 |
Turner JG, Rowe TC, Ostrov DA, Ciaravino EJ, Gump JL, Sullivan DM. Blocking a Topoisomerase IIα Nuclear Export Signal Sensitizes Human Multiple Myeloma Cells to Topoisomerase II Inhibitors. Blood. 114: 2850-2850. DOI: 10.1182/Blood.V114.22.2850.2850 |
0.465 |
|
| 2008 |
Turner JG, Sullivan DM. CRM1-mediated nuclear export of proteins and drug resistance in cancer. Current Medicinal Chemistry. 15: 2648-55. PMID 18991627 DOI: 10.2174/092986708786242859 |
0.405 |
|
| 2008 |
Sullivan D, Dawson JL, Ciaravino EJ, Turner JG. Intrinsic Drug Resistance in Multiple Myeloma to Doxorubicin Is Mediated by Soluble Factors Blood. 112: 5106-5106. DOI: 10.1182/Blood.V112.11.5106.5106 |
0.419 |
|
| 2006 |
Turner JG, Gump JL, Zhang C, Cook JM, Marchion D, Hazlehurst L, Munster P, Schell MJ, Dalton WS, Sullivan DM. ABCG2 expression, function, and promoter methylation in human multiple myeloma. Blood. 108: 3881-9. PMID 16917002 DOI: 10.1182/Blood-2005-10-009084 |
0.419 |
|
| 2006 |
Nakanishi T, Bailey-Dell KJ, Hassel BA, Shiozawa K, Sullivan DM, Turner J, Ross DD. Novel 5' untranslated region variants of BCRP mRNA are differentially expressed in drug-selected cancer cells and in normal human tissues: implications for drug resistance, tissue-specific expression, and alternative promoter usage. Cancer Research. 66: 5007-11. PMID 16707421 DOI: 10.1158/0008-5472.Can-05-4572 |
0.395 |
|
| 2005 |
Marchion DC, Bicaku E, Turner JG, Daud AI, Sullivan DM, Munster PN. Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 8467-75. PMID 16322310 DOI: 10.1158/1078-0432.Ccr-05-1073 |
0.379 |
|
| 2005 |
Cook AC, Tuck AB, McCarthy S, Turner JG, Irby RB, Bloom GC, Yeatman TJ, Chambers AF. Osteopontin induces multiple changes in gene expression that reflect the six "hallmarks of cancer" in a model of breast cancer progression. Molecular Carcinogenesis. 43: 225-36. PMID 15864800 DOI: 10.1002/Mc.20105 |
0.341 |
|
| 2005 |
Sung J, Turner J, McCarthy S, Enkemann S, Li CG, Yan P, Huang T, Yeatman TJ. Oncogene regulation of tumor suppressor genes in tumorigenesis. Carcinogenesis. 26: 487-94. PMID 15498783 DOI: 10.1093/Carcin/Bgh318 |
0.313 |
|
| 2004 |
Chen T, Turner J, McCarthy S, Scaltriti M, Bettuzzi S, Yeatman TJ. Clusterin-mediated apoptosis is regulated by adenomatous polyposis coli and is p21 dependent but p53 independent. Cancer Research. 64: 7412-9. PMID 15492264 DOI: 10.1158/0008-5472.Can-04-2077 |
0.372 |
|
| 2004 |
Turner JG, Engel R, Derderian JA, Jove R, Sullivan DM. Human topoisomerase IIalpha nuclear export is mediated by two CRM-1-dependent nuclear export signals. Journal of Cell Science. 117: 3061-71. PMID 15173319 DOI: 10.1242/Jcs.01147 |
0.345 |
|
| 2004 |
Sung JC, McCarthy S, Turner J, Li C, Yeatman TJ. The NBL1 tumor suppressor gene is downregulated in colon cancer by promoter methylation Journal of the American College of Surgeons. 199: 92. DOI: 10.1016/J.Jamcollsurg.2004.05.200 |
0.331 |
|
| 2001 |
Chang AE, Tanigawa K, Turner JG, Chang EC, Yu H. Use of gene gun for genetic immunotherapy : in vitro and in vivo methods. Methods in Molecular Medicine. 61: 223-40. PMID 22323261 DOI: 10.1385/1-59259-145-0:223 |
0.304 |
|
| 2001 |
Turner JG, Rakhmilevich AL, Burdelya L, Neal Z, Imboden M, Sondel PM, Yu H. Anti-CD40 antibody induces antitumor and antimetastatic effects: The role of NK cells Journal of Immunology. 166: 89-94. PMID 11123280 DOI: 10.4049/Jimmunol.166.1.89 |
0.311 |
|
| 2000 |
Shtil AA, Turner JG, Dalton WS, Yu H. Alternative pathways of cell death to circumvent pleiotropic resistance in myeloma cells: role of cytotoxic T-lymphocytes. Leukemia & Lymphoma. 38: 59-70. PMID 10811448 DOI: 10.3109/10428190009060319 |
0.421 |
|
| 1999 |
Shtil AA, Turner JG, Durfee J, Dalton WS, Yu H. Cytokine-based tumor cell vaccine is equally effective against parental and isogenic multidrug-resistant myeloma cells: the role of cytotoxic T lymphocytes. Blood. 93: 1831-1837. DOI: 10.1182/Blood.V93.6.1831.406K38_1831_1837 |
0.419 |
|
| 1999 |
Seigne J, Turner J, Diaz J, Hackney J, Pow-Sang J, Helal M, Lockhart J, Yu H. A feasibility study of gene gun mediated immunotherapy for renal cell carcinoma. The Journal of Urology. 162: 1259-1263. DOI: 10.1016/S0022-5347(05)68260-2 |
0.341 |
|
| 1998 |
Ye ZQ, Qiu P, Burkholder JK, Turner J, Culp J, Roberts T, Shahidi NT, Yang NS. Cytokine transgene expression and promoter usage in primary CD34+ cells using particle-mediated gene delivery. Human Gene Therapy. 9: 2197-205. PMID 9794204 DOI: 10.1089/Hum.1998.9.15-2197 |
0.34 |
|
| 1998 |
Turner JG, Tan J, Crucian BE, Sullivan DM, Ballester OF, Dalton WS, Yang NS, Burkholder JK, Yu H. Broadened clinical utility of gene gun-mediated, granulocyte-macrophage colony-stimulating factor cDNA-based tumor cell vaccines as demonstrated with a mouse myeloma model. Human Gene Therapy. 9: 1121-30. PMID 9625251 DOI: 10.1089/Hum.1998.9.8-1121 |
0.377 |
|
| 1997 |
Mao W, Irby R, Coppola D, Fu L, Wloch M, Turner J, Yu H, Garcia R, Jove R, Yeatman TJ. Activation of c-Src by receptor tyrosine kinases in human colon cancer cells with high metastatic potential Oncogene. 15: 3083-3090. PMID 9444956 DOI: 10.1038/Sj.Onc.1201496 |
0.318 |
|
| 1996 |
Mahvi DM, Burkholder JK, Turner J, Culp J, Malter JS, Sondel PM, Yang NS. Particle-mediated gene transfer of granulocyte-macrophage colony-stimulating factor cDNA to tumor cells: Implications for a clinically relevant tumor vaccine Human Gene Therapy. 7: 1535-1543. PMID 8864754 DOI: 10.1089/Hum.1996.7.13-1535 |
0.367 |
|
| 1996 |
Rakhmilevich AL, Turner J, Ford MJ, Mccabe D, Sun WH, Sondel PM, Grota K, Yang NS. Gene gun-mediated skin transfection with interleukin 12 gene results in regression of established primary and metastatic murine tumors Proceedings of the National Academy of Sciences of the United States of America. 93: 6291-6296. PMID 8692808 DOI: 10.1073/Pnas.93.13.6291 |
0.331 |
|
| Show low-probability matches. |